Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Tumor-Agnostic 2Thoracic 2Gastrointestinal 2CNS 2Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × LY2940680 × Sarcoma × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT01697514 2013-08-27

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Eli Lilly and Company

Phase 1 Withdrawn
CNSSarcoma

Medulloblastoma, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡